Dynavax Technologies | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
AbbVie USD 3.25B 40M 2025-06
Adma Biologics USD 24.59M 5.01M 2024-12
Amgen USD 1.69B 4M 2025-06
AstraZeneca USD 5.01B 1.42B 2025-06
Biogen USD 583.8M 11.3M 2025-06
BioMarin Pharmaceutical USD 232.28M 26.16M 2025-06
Bristol-Myers Squibb USD 1.71B 129M 2025-06
Dynavax Technologies USD 41.54M 64.79M 2025-06
Gilead Sciences USD 1.36B 100M 2025-06
Glaxosmithkline GBP 2.7B 632M 2024-12
Merck USD 2.63B 104M 2025-06
Neurocrine Biosciences USD 286.3M 9.8M 2025-06
Novartis USD 3.44B 384M 2025-06
Pfizer USD 3.42B 406M 2025-06
Regeneron Pharmaceuticals USD 634.2M 1.2M 2025-06
Roche Holding CHF 3.61B 381M 2024-12
Sarepta Therapeutics USD 69.89M 63.74M 2025-06
TG Therapeutics USD 12.04M 38.29M 2025-06
Vertex Pharmaceuticals USD 424.6M 28.2M 2025-06


Dynavax Technologies Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Aug 2025.